Breaking News Instant updates and real-time market news.

GLMD

Galmed

$6.27

-0.11 (-1.72%)

07:50
07/22/19
07/22
07:50
07/22/19
07:50

Galmed initiated with a Buy at Laidlaw

Laidlaw analyst Francois Brisebois initiated Galmed with a Buy rating and $25 price target, citing his belief that the company's Aramchol could be a "great candidate" for a combination treatment for Nonalcoholic Steatohepatitis, or NASH. Galmed expects to initiate a Phase 3/4 trial of Aramchol in Q3 and report data from its first part by the end of 2022, Brisebois noted.

GLMD Galmed
$6.27

-0.11 (-1.72%)

12/11/18
RILY
12/11/18
INITIATION
Target $28
RILY
Buy
Galmed initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Mayank Mamtani started Galmed Pharmaceuticals with a Buy rating and $28 price target.
12/12/18
RILY
12/12/18
INITIATION
RILY
B. Riley FBR rolls out coverage on NASH players with three Buy ratings
B. Riley FBR analyst Mayank Mamtani last night initiated coverage of four companies working on developing drugs to treat nonalcoholic steatohepatitis. The analyst started Galmed Pharmaceuticals (GLMD) with a Buy rating and $28 price target, Intercept Pharmaceuticals (ICPT) with a Buy rating and $155 price target, Viking Therapeutics (VKTX) with a Buy rating and $16 price target, and Madrigal Pharmaceuticals (MDGL) with a Neutral rating and $124 price target. NASH disease burden is "poised to create the next liver transplant crisis" and is drawing significant investments from the biotech industry, Mamtani writes in a research note. He points out that Intercept's obeticholic acid is the only NASH drug to have the FDA's breakthrough therapy designation for strong anti-fibrotic efficacy and be previously approved by the FDA, for an orphan liver indication. His proprietary safety analysis suggests the Street should gain comfort in drug's cardiovascular profile going into pivotal readout in Q2 of 2019. Mamtani believes Viking's lead drug, VK2809, has an "excellent" safety and tolerability profile that assuages concerns of any off-target effects. Further, his comparator analysis suggests efficacy in high-dose of Galmed's Aramchol drug "represents a compelling clinical profile on both regulatory acceptable endpoints."
12/12/18
12/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Foamix (FOMX) initiated with a Buy at BofA/Merrill. 2. Jazz Pharmaceuticals (JAZZ) initiated with an Outperform at Oppenheimer while GW Pharmaceuticals (GWPH) was initiated with a Perform. 3. Six Flags (SIX) initiated with a Buy at Berenberg. 4. iQIYI (IQ) initiated with a Hold at HSBC. 5. Intercept (ICPT), Viking Therapeutics (VKTX), and Galmed (GLMD) were initiated with a Buy at B. Riley FBR, while Madrigal Pharmaceuticals (MDGL) initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/14/19
HCWC
01/14/19
NO CHANGE
Target $28
HCWC
Buy
Galmed price target lowered to $28 from $36 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce lowered his price target for Galmed Pharmaceuticals to $28 after shifting the U.S. launch of Aramchol out to 2022 from 2021 previously. However, with a pivotal path forward for Aramchol, which the analyst notes has been granted Fast Track designation by the FDA for the treatment of nonalcoholic steatohepatitis, he affirms a Buy rating on Galmed shares.

TODAY'S FREE FLY STORIES

CLVS

Clovis

$4.76

-0.1 (-2.06%)

05:38
09/23/19
09/23
05:38
09/23/19
05:38
Hot Stocks
Clovis acquires rights to FAP »

Clovis Oncology has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

TRV

Travelers

$146.32

-0.69 (-0.47%)

05:37
09/23/19
09/23
05:37
09/23/19
05:37
Hot Stocks
Travelers receives approval to transfer European business to Dublin »

Travelers announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

DEA

Easterly Government Properties

$20.96

0.02 (0.10%)

05:37
09/23/19
09/23
05:37
09/23/19
05:37
Initiation
Easterly Government Properties initiated  »

Easterly Government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

TEL

TE Connectivity

$93.21

-1.21 (-1.28%)

05:34
09/23/19
09/23
05:34
09/23/19
05:34
Downgrade
TE Connectivity rating change  »

TE Connectivity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWDBY

Swedbank

$0.00

(0.00%)

05:33
09/23/19
09/23
05:33
09/23/19
05:33
Upgrade
Swedbank rating change  »

Swedbank upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESLOY

EssilorLuxottica

$0.00

(0.00%)

05:32
09/23/19
09/23
05:32
09/23/19
05:32
Upgrade
EssilorLuxottica rating change  »

EssilorLuxottica upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHWY

Chewy

$26.44

-1.06 (-3.85%)

05:30
09/23/19
09/23
05:30
09/23/19
05:30
Upgrade
Chewy rating change  »

Chewy upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEXAY

Atos

$0.00

(0.00%)

05:29
09/23/19
09/23
05:29
09/23/19
05:29
Upgrade
Atos rating change  »

Atos upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$238.80

3.2 (1.36%)

05:28
09/23/19
09/23
05:28
09/23/19
05:28
Hot Stocks
Biogen says Plegridy, Avonex receive 'positive opinion' from CHMP »

Biogen announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

ACN

Accenture

$192.99

-1.78 (-0.91%)

05:28
09/23/19
09/23
05:28
09/23/19
05:28
Initiation
Accenture initiated  »

Accenture initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Oct

TELDF

Telefonica Deutschland

$0.00

(0.00%)

05:27
09/23/19
09/23
05:27
09/23/19
05:27
Upgrade
Telefonica Deutschland rating change  »

Telefonica Deutschland…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGY

VAALCO Energy

$2.08

0.06 (2.97%)

05:26
09/23/19
09/23
05:26
09/23/19
05:26
Initiation
VAALCO Energy initiated  »

VAALCO Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$11.64

-0.565 (-4.63%)

05:25
09/23/19
09/23
05:25
09/23/19
05:25
Hot Stocks
PG&E expects to turn off power late Monday in nine CA counties due to fire risk »

Pacific Gas and Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Oct

  • 10

    Nov

  • 10

    Nov

  • 07

    Jan

AIBRF

AIB Group

$0.00

(0.00%)

05:25
09/23/19
09/23
05:25
09/23/19
05:25
Upgrade
AIB Group rating change  »

AIB Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OAOFY

Tatneft

$0.00

(0.00%)

05:22
09/23/19
09/23
05:22
09/23/19
05:22
Downgrade
Tatneft rating change  »

Tatneft downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESYJY

easyJet

$0.00

(0.00%)

05:21
09/23/19
09/23
05:21
09/23/19
05:21
Upgrade
easyJet rating change  »

easyJet upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLOWY

Vallourec

$0.00

(0.00%)

05:20
09/23/19
09/23
05:20
09/23/19
05:20
Downgrade
Vallourec rating change  »

Vallourec downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TELNY

Telenor

$0.00

(0.00%)

05:15
09/23/19
09/23
05:15
09/23/19
05:15
Downgrade
Telenor rating change  »

Telenor downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANNSF

Aena

$0.00

(0.00%)

05:14
09/23/19
09/23
05:14
09/23/19
05:14
Downgrade
Aena rating change  »

Aena downgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$217.69

-3.22 (-1.46%)

05:13
09/23/19
09/23
05:13
09/23/19
05:13
Recommendations
Apple analyst commentary  »

Piper survey shows higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXCM

DexCom

$154.45

-0.49 (-0.32%)

, ABT

Abbott

$83.56

0.35 (0.42%)

05:04
09/23/19
09/23
05:04
09/23/19
05:04
Recommendations
DexCom, Abbott analyst commentary  »

DexCom remains a…

DXCM

DexCom

$154.45

-0.49 (-0.32%)

ABT

Abbott

$83.56

0.35 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 16

    Oct

  • 13

    Nov

EW

Edwards Lifesciences

$219.56

4.45 (2.07%)

04:58
09/23/19
09/23
04:58
09/23/19
04:58
Initiation
Edwards Lifesciences initiated  »

Edwards Lifesciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITW

Illinois Tool Works

$155.05

-0.91 (-0.58%)

, HON

Honeywell

$168.42

1.7 (1.02%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Downgrade
Illinois Tool Works, Honeywell rating change  »

Illinois Tool Works…

ITW

Illinois Tool Works

$155.05

-0.91 (-0.58%)

HON

Honeywell

$168.42

1.7 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

HR

Healthcare Realty Trust

$33.17

-0.155 (-0.47%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Healthcare Realty Trust management to meet with Capital One »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

NBIX

Neurocrine

$100.74

-0.77 (-0.76%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Neurocrine participates in a conference call with JPMorgan »

SMid Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.